News Channels

03 Oct 2017 OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment
03 Oct 2017 Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting
03 Oct 2017 AmpliPhi Biosciences Announces Publication of Preclinical Data for AB-PA01 Showing Activity in Reducing Biofilms of Pseudomonas Aeruginosa
03 Oct 2017 Seres Therapeutics reports positive topline results from SER-287 phase 1b study in patients with ulcerative colitis
03 Oct 2017 PnuVax Awarded $29.4 Million USD Grant to Advance Innovative Vaccine into Clinical Trials
03 Oct 2017 Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
03 Oct 2017 Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer
03 Oct 2017 Ablynx announces positive topline results from the phase III HERCULES study of caplacizumab for the treatment of acquired TTP
03 Oct 2017 VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
03 Oct 2017 Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
03 Oct 2017 FDA Accepts Supplemental New Drug Application (sNDA) filing for AVYCAZ® (ceftazidime and avibactam)
03 Oct 2017 Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia
03 Oct 2017 Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
03 Oct 2017 Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
03 Oct 2017 Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
03 Oct 2017 Takeda Announces Positive Results from its Phase 3 Confirmatory Clinical Trial in Japan Evaluating the Efficacy and Safety of GnRH Receptor Antagonist Relugolix in Uterine Fibroids
03 Oct 2017 Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
30 Sep 2017 Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer
30 Sep 2017 Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
30 Sep 2017 Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing